恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01276 恒瑞医药

已收盘 12-16 16:08:20

70.850

-1.500

-2.07%

最高73.250	最低69.850	成交量243.13万
今开72.900	昨收72.350	日振幅4.70%
总市值4,702亿	流通市值182.79亿	总股本66.37亿
成交额1.72亿	换手率0.94%	流通股本2.58亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"恒瑞医药","latestPrice":70.85,"timestamp":1765872500003,"preClose":72.35,"halted":0,"volume":2431300,"delay":0,"floatShares":258000000,"shares":6637000000,"eps":1.1061070483896065,"marketStatus":"已收盘","change":-1.5,"latestTime":"12-16 16:08:20","open":72.9,"high":73.25,"low":69.85,"amount":172084456,"amplitude":0.046994,"askPrice":71.15,"askSize":600,"bidPrice":70.85,"bidSize":2600,"shortable":3,"etf":0,"ttmEps":1.2833142463980085,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765935000000},"marketStatusCode":5,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":72.35,"openAndCloseTimeList":[[1765848600000,1765857600000],[1765861200000,1765872000000]],"volumeRatio":0.656136,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"恒瑞医药","latestPrice":59.15,"timestamp":1765868400000,"preClose":61.38,"halted":0,"volume":52378400,"delay":0,"premium":"+8.29"}},"requestUrl":"/m/hq/s/01276/wiki","defaultTab":"wiki","newsList":[{"id":"2591022646","title":"东方财富证券：创新浪潮涌动下 关注医药板块修复与突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2591022646","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591022646?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:25","pubTimestamp":1765873557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方财富证券发布研报称，随着中国创新药License-out项目总金额创下新纪录，临床前项目占比持续保持高位，ADC、双/多抗、小核酸等新兴疗法，以及代谢领域中肥胖适应症等或为未来License-out项目的重点方向。东方财富证券主要观点如下：今年以来，在创新药、AI医疗的带动下，化学制药板块领涨医药板块估值水平接近最近10年历史平均水平。中国创新药十年变革主要得益于全面的监管改革、研发投入的增加以及战略性的全球化布局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382080.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","SG9999014674.SGD","LU0307460666.USD","IE00BZ08YS42.EUR","LU2543165471.USD","LU1997244956.HKD","LU0588546209.SGD","09939","BK0188","LU2097828805.USD","BK0095","159938","BK0077","BK0028","LU2148510915.USD","BK1521","BK1191","LU1719994722.HKD","LU2328871848.SGD","LU0326950275.SGD","IE00BZ08YR35.GBP","LU1064131003.USD","LU1997245177.USD","01177","LU0359202008.SGD","LU1969619763.USD","LU2097828631.EUR","HK0000165453.HKD","LU2495084118.USD","LU2097828714.EUR","300059","BK1583","IE00BZ08YT58.USD","LU2580892789.USD","06160","01276","LU1303224171.USD","LU1831875114.USD","161027","BK1500","LU2289578879.USD","BK1515","BK0196","LU2097828474.EUR","LU2097828557.USD","LU1770034418.SGD","BK1588","BK1589","LU1251922891.USD"],"gpt_icon":0},{"id":"2591264877","title":"小摩增持恒瑞医药(01276)387.9413万股 每股作价72.5974港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591264877","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591264877?lang=zh_cn&edition=full","pubTime":"2025-12-15 18:59","pubTimestamp":1765796342,"startTime":"0","endTime":"0","summary":"增持后最新持股数目约为2141.30万股，最新持股比例为8.29%。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251215/20251215185921_56798.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["IE00BJLML261.HKD","IE00BKDWB100.SGD","BK4585","LU2552382215.SGD","LU0345769128.USD","LU0942090050.USD","BK4207","LU1116320737.USD","LU2462157665.USD","LU1064130708.USD","LU0211326755.USD","LU0868494617.USD","LU2592432038.USD","LU1244550494.USD","LU2756315664.SGD","LU1551013342.USD","BK0012","BK4550","BK4566","LU1551013425.SGD","LU1366192091.USD","LU0211328371.USD","IE00BJTD4N35.SGD","LU2097828805.USD","LU1988902786.USD","LU0496365809.HKD","LU0267386448.USD","LU0359202008.SGD","LU1146622755.USD","LU0405327494.USD","BK4588","LU0048584097.USD","LU2417539215.USD","LU2495084118.USD","LU1997244956.HKD","01276","LU0964807845.USD","600276","IE00BN8TJ469.HKD","LU0820561818.USD","LU1997245177.USD","LU2237443895.HKD","BK4504","LU2213496289.HKD","LU0170899867.USD","LU0405327148.USD","LU2456880835.USD","LU2552382058.USD","IE00BFXG1179.USD","IE00BKVL7J92.USD"],"gpt_icon":0},{"id":"2591453816","title":"每日卖空追踪 | 恒瑞医药 12月15日卖空量成交8.22万股，卖空比例为2.92%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591453816","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591453816?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:30","pubTimestamp":1765787419,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间12月15日，跌0.14%，卖空量成交8.22万股，较上一交易日减少88.89%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163258a6a455c9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215163258a6a455c9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU1023057109.AUD","LU0359202008.SGD","LU2543165471.USD","LU0359201612.USD","LU0359201885.HKD","01276"],"gpt_icon":0},{"id":"2591645352","title":"恒瑞医药12月15日遭主力抛售649.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591645352","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591645352?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:16","pubTimestamp":1765786564,"startTime":"0","endTime":"0","summary":"12月15日, 恒瑞医药股价跌0.14%，报收72.35元，成交金额2.0亿元，换手率1.09%，振幅3.66%，量比0.78。恒瑞医药今日主力资金净流出649.6万元，连续3日净流出，上一交易日主力净流出1605.4万元。该股近5个交易日上涨0.55%，主力资金累计净流出1722.7万元；近20日主力资金累计净流入1.2亿元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215162256a44d32d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215162256a44d32d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2543165471.USD","BK1191","LU1023057109.AUD","LU0359201612.USD","LU0359201885.HKD","LU0359202008.SGD","01276"],"gpt_icon":0},{"id":"2591616750","title":"智通AH统计|12月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616750?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786506,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月15日收盘，东北电气、京城机电股份、弘业期货分列AH溢价率前三位，溢价率分别为900.00%、266.67%、265.78%；宁德时代、招商银行、恒瑞医药分列AH溢价率末三位，溢价率分别为-11.03%、-0.77%、1.62%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381502.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02865","02899","159982","06127","IE00B29SXG58.USD","01276","00042","LU0348827113.USD","LU0244354667.USD","01108","01339","LU1105468828.SGD","LU1522347837.USD","01988","06826","00638","01349","02238","00187","LU1504937902.USD","02218","BK1565","00038","00300","BK1562","01812","02359","03143","00177","03678","00553","BK1594","06818","LU0823426480.USD","01057","02338","00548","01033","00317","01528","01618","03968","00916","399300","LU0886674414.USD","03750","03606"],"gpt_icon":1},{"id":"2591960609","title":"12月以来，药明巨诺、恒瑞医药、南新制药等大批药企高管变动！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591960609","media":"制药网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591960609?lang=zh_cn&edition=full","pubTime":"2025-12-15 15:54","pubTimestamp":1765785283,"startTime":"0","endTime":"0","summary":"年末，国内医药行业高管变动进入密集期。根据梳理，近期，多家药企发布高管变动公告，涉及药明巨诺、恒瑞医药、南新制药、康恩贝等。12月10日，南新制药发布公告，宣布原非独立董事彭程因个人原因辞去相关职务，副总经理兼财务总监李亮因工作调整辞任。除了以上企业，12月以来，百奥赛图、维康药业、复锐医疗也有高管因个人原因、工作调动等原因辞任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216085448a6a70ec0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216085448a6a70ec0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","LU0359202008.SGD","LU0359201885.HKD","BK1574","LU1023057109.AUD","LU2543165471.USD","BK1161","01276","02126","LU0359201612.USD","BK1191"],"gpt_icon":0},{"id":"2591970396","title":"恒瑞医药卵巢癌治疗药物氟唑帕利FZOCUS-1研究，载入全球肿瘤学顶刊《CA》","url":"https://stock-news.laohu8.com/highlight/detail?id=2591970396","media":"新浪科技","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591970396?lang=zh_cn&edition=full","pubTime":"2025-12-15 13:59","pubTimestamp":1765778340,"startTime":"0","endTime":"0","summary":"新浪科技讯 12月15日下午消息，近日，FZOCUS-1研究登顶全球肿瘤学顶级期刊《临床医师癌症杂志》 ，这也是《CA》首次刊载由中国研究者开展的妇科肿瘤领域临床研究。在HRD阳性人群，FZOCUS-1研究证实PARP抑制剂单药运用即可实现理想疗效，避免联合用药带来的副作用与经济负担。　　“FZOCUS-1研究全文在《CA》的成功发表，是中国临床肿瘤学研究的重要里程碑。”","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/tech/shenji/2025-12-15/doc-inhawiaf2341954.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0196","LU1328615791.USD","LU0359201885.HKD","LU2097828631.EUR","LU1969619763.USD","LU0359201612.USD","LU2543165471.USD","LU2289578879.USD","LU1255011170.USD","LU1997245094.SGD","LU2097828474.EUR","LU1997245177.USD","600276","BK0028","LU2580892862.HKD","LU1064130708.USD","LU2580892789.USD","BK0183","LU0359202008.SGD","01276","LU1781817850.SGD","LU0405327494.USD","CA","LU1023057109.AUD","LU2488822045.USD","LU2097828714.EUR","LU1064131003.USD","BK0188","LU2097828805.USD","BK0012","LU1997244956.HKD","LU0405327148.USD","LU1580142542.USD","LU2148510915.USD","LU1820825898.SGD","LU2328871848.SGD","BK0239","BK0060","LU2495084118.USD","LU2097828557.USD","BK1191","LU1655091616.SGD","LU1146622755.USD"],"gpt_icon":1},{"id":"2591699288","title":"国信证券：FXI抑制剂有望成为下一代抗凝药物 建议关注恒瑞医药(600276.SH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2591699288","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591699288?lang=zh_cn&edition=full","pubTime":"2025-12-15 10:41","pubTimestamp":1765766465,"startTime":"0","endTime":"0","summary":"建议关注恒瑞医药：FXI单抗SHR-2004进入3期临床，在国产分子中领先;并关注拥有FXI小核酸药物管线的公司。国信证券主要观点如下：FXI/FXIa抑制剂有望成为安全性更优的抗凝药物现有抗凝血药物均作用于凝血的共同通路，FXI仅参与内源性凝血通路以及血栓的正反馈放大，抑制FXI活性有望在抗凝血的同时减少出血的风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1381384.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2097828474.EUR","BK0183","LU1997245177.USD","LU0359201885.HKD","BK0012","LU2097828714.EUR","LU0405327494.USD","LU2495084118.USD","LU2097828557.USD","BK0028","LU1064131003.USD","BK0276","BK0239","LU2488822045.USD","LU0359202008.SGD","BK0196","BK0060","LU1997245094.SGD","LU1969619763.USD","600276","LU1781817850.SGD","LU1580142542.USD","01276","BK1191","LU0359201612.USD","LU2543165471.USD","LU2289578879.USD","LU1023057109.AUD","BK0188","LU1064130708.USD","LU1820825898.SGD","LU1255011170.USD","LU1997244956.HKD","LU1146622755.USD","LU2097828805.USD","LU0405327148.USD","LU2148510915.USD","LU1328615791.USD","LU2580892862.HKD","LU2328871848.SGD","002736","LU2097828631.EUR","LU1655091616.SGD","LU2580892789.USD"],"gpt_icon":0},{"id":"2591660538","title":"国产创新药迎利好密集期！九安医疗产品获FDA批准，一品红斩获近70亿元大单","url":"https://stock-news.laohu8.com/highlight/detail?id=2591660538","media":"21世纪经济报道","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591660538?lang=zh_cn&edition=full","pubTime":"2025-12-15 07:27","pubTimestamp":1765754852,"startTime":"0","endTime":"0","summary":"九安医疗公告，公司美国子公司四联检、三联检产品获得美国FDA上市前通知，涉及的产品包括甲型流感、乙型流感、COVID-19及RSV呼吸道合胞病毒四联检测家用试剂盒等。一品红公告，芩香清解口服液获批国家中药二级保护品种。这些优势使中国药企在全球医药交易中的占比迅速提升，2025年成为中国创新药对外授权交易的爆发之年。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215073159a44b653b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215073159a44b653b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01801","BK1583","LU2242644610.SGD","LU0502904849.HKD","LU2097828714.EUR","LU2097828805.USD","HK0000165453.HKD","BK1589","LU1969619763.USD","06978","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU2097828557.USD","01877","BK1574","LU2488822045.USD","LU0455707207.USD","01276","03692","BK1161"],"gpt_icon":0},{"id":"2591663795","title":"周评 | 首批商保创新药目录出炉，只是万里长征的第一步！","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663795","media":"中保新知","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663795?lang=zh_cn&edition=full","pubTime":"2025-12-14 19:28","pubTimestamp":1765711720,"startTime":"0","endTime":"0","summary":"近日，国家医保局正式发布首版《商业健康保险创新药品目录》，包括CAR-T等19种高价药品。硬币两面《目录》更重要的是明确了商保在多层次医疗保障体系中的地位和定位，此前惠民保等产品其实已经将CAR-T等动辄百万元的药品纳入保障范围，因此就高价药和创新药而言，《目录》并不是石破天惊的第一次。人们常用“最后一公里”来形容，其实更像是万里长征第一步之后的砥砺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214193959a449fe90&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214193959a449fe90&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["PAImain","LU0878005551.USD","LU0348788117.USD","LU0648948544.HKD","LU0315179316.USD","LU0051755006.USD","LU0348816934.USD","LU1366334651.USD","LU0823426308.USD","LU0918141887.USD","LU0417516571.SGD","LU2476274308.USD","02318","601318","HK0000320264.USD","LU0594300179.USD","LU0880133367.SGD","LU1044876610.USD","PNGAY","IE00BZ08YR35.GBP","LU0149721374.USD","82318","01276","LU0039217434.USD","LU1794554557.SGD","LU2348774022.SGD","LU0762541174.USD","IE00BMCWC346.EUR","LU1366334578.USD","LU0196878994.USD","LU0067412154.USD","IE0034224299.USD","BK1550","HPAD.SI","LU0314109678.HKD","LU0348783233.USD","LU0630378429.USD","LU0828237940.HKD","LU2226246903.HKD","03145","SG9999002463.SGD","LU0640798160.USD","LU0878004406.USD","IE00BGHQDM52.EUR","LU1048588211.SGD","IE0003895053.USD","LU0630378692.HKD","06978","LU0588545490.SGD","LU0348735423.USD","LU0054450605.USD"],"gpt_icon":1},{"id":"2591663796","title":"医疗与消费周报：创新药行业研发突破与市场演进的并行","url":"https://stock-news.laohu8.com/highlight/detail?id=2591663796","media":"华福证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591663796?lang=zh_cn&edition=full","pubTime":"2025-12-14 16:08","pubTimestamp":1765699711,"startTime":"0","endTime":"0","summary":"投资要点：近期观点1、医药指数本周关注的6个子行业只有一个录得正收益。新药分为强调全新结构的1类（创新药）与强调临床优势的2类。近年来产业规模持续扩大，从2020年约8198亿元增至2024年1.14万亿元，年均复合增长率达8.53%，预计2025年将达1.22万亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214160834a44985a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251214160834a44985a0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU1770034418.SGD","LU0307460666.USD","06978","06160","BK1583","02359","BK1588","LU1251922891.USD","01276","BK1161","LU2328871848.SGD","LU1303224171.USD","LU0588546209.SGD","LU1969619763.USD","LU1719994722.HKD","BK1574"],"gpt_icon":0},{"id":"2590570693","title":"智通港股空仓持单统计|12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2590570693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590570693?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:30","pubTimestamp":1765535405,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，截止12月5日，未平仓空单比位列前三位为万科企业、中兴通讯、中远海控，空仓比分别为20.57%、17.63%、17.59%。智通机器人根据港交所数据，经过人工智能运算后自动生成，并不保证数据100%准确；以上涉及的空仓比增加值或减少值为绝对值数。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09995","LU0235996351.USD","02228","03145","HPAD.SI","PNGAY","02382","LU0417516738.SGD","02202","02013","01880","02498","01138","LU0315179316.USD","LU1481107354.HKD","09626","01801","02899","00522","PAImain","06613","06865","LU2242644610.SGD","601318","LU2476274720.SGD","LU2097828631.EUR","01276","LU1211504680.USD","000002","LU0348767384.USD","00763","IE00BZ08YR35.GBP","82318","01919","06680","SG9999002463.SGD","00839","09863","LU0821914370.USD","LU0320764599.SGD","01530","HK0000306685.HKD","00354","01072","LU0370786039.SGD","SG9999004220.SGD","00863"],"gpt_icon":1},{"id":"2590577652","title":"12月12日恒瑞医药现1笔大宗交易 机构净卖出358.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577652","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577652?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:57","pubTimestamp":1765533451,"startTime":"0","endTime":"0","summary":"证券之星消息，12月12日恒瑞医药发生大宗交易，交易数据如下：大宗交易成交价格63.28元，成交5.66万股，成交金额358.16万元，买方营业部为国泰海通证券股份有限公司总部，卖方营业部为机构专用。近三个月该股共发生3笔大宗交易，合计成交1.12万手。截至2025年12月12日收盘，恒瑞医药报收于63.28元，下跌0.19%，换手率0.49%，成交量31.56万手，成交额19.85亿元。该股最近90天内共有22家机构给出评级，买入评级21家，增持评级1家；过去90天内机构目标均价为83.75。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029064.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","LU2289578879.USD","LU1064130708.USD","LU2097828557.USD","LU2097828805.USD","LU2097828631.EUR","BK0012","LU0405327494.USD","LU2488822045.USD","LU2148510915.USD","LU0405327148.USD","LU1997245094.SGD","600276","01276","LU1580142542.USD","LU1781817850.SGD","LU1997245177.USD","LU2543165471.USD","BK0028","BK0196","LU1328615791.USD","BK0183","LU1969619763.USD","LU2097828714.EUR","LU2580892789.USD","LU1255011170.USD","BK0239","LU1146622755.USD","LU2097828474.EUR","LU1064131003.USD","BK0188","LU1820825898.SGD","LU1655091616.SGD","LU1997244956.HKD","LU2328871848.SGD","LU2580892862.HKD","LU2495084118.USD","LU0359201612.USD","LU1023057109.AUD","LU0359201885.HKD","BK0060","LU0359202008.SGD"],"gpt_icon":0},{"id":"2590574915","title":"恒瑞医药：SHR-A1811(sc)注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590574915","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590574915?lang=zh_cn&edition=full","pubTime":"2025-12-12 17:06","pubTimestamp":1765530411,"startTime":"0","endTime":"0","summary":"南财智讯12月12日电，恒瑞医药公告，恒瑞医药收到国家药品监督管理局核准签发的关于SHR-A1811(sc)注射液的《药物临床试验批准通知书》，同意该药品单药在晚期实体瘤患者中开展临床试验。SHR-A1811(sc)注射液为公司开发的皮下制剂，是在已获批上市的注射用瑞康曲妥珠单抗（SHR-A1811）基础上优化而来，旨在缩短给药时间、提升便捷性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512123590226438.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1997245094.SGD","BK0183","LU1255011170.USD","BK1191","LU1820825898.SGD","LU0405327494.USD","01276","LU1969619763.USD","LU1997245177.USD","600276","BK0196","LU2543165471.USD","LU2097828474.EUR","LU2097828631.EUR","LU0359202008.SGD","LU2580892789.USD","BK0028","LU1997244956.HKD","LU1023057109.AUD","LU2097828557.USD","LU2488822045.USD","LU2097828714.EUR","LU0405327148.USD","LU2495084118.USD","LU1580142542.USD","LU2097828805.USD","LU1064131003.USD","LU1146622755.USD","LU1328615791.USD","LU0359201612.USD","LU1781817850.SGD","BK0060","LU1064130708.USD","LU2580892862.HKD","BK0012","LU0359201885.HKD","LU2289578879.USD","LU2328871848.SGD","LU2148510915.USD","BK0188","BK0239","LU1655091616.SGD"],"gpt_icon":0},{"id":"2590579960","title":"恒瑞医药 30 款 1 类新药首次获批临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2590579960","media":"丁香园 Insight 数据库","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590579960?lang=zh_cn&edition=full","pubTime":"2025-12-12 16:01","pubTimestamp":1765526475,"startTime":"0","endTime":"0","summary":"2025 年以来，恒瑞共有30 款 1 类新药首次获批临床，包括 17 款化药和 13 款生物制品。SHR-4610：PD1/VEGF 双抗今年 10 月 20 日，SHR-4610 在国内首次获批临床，用于治疗实体瘤。HRS-5817：siRNA 肥胖疗法今年 3 月 22 日，HRS-5817 在国内首次获批临床，用于治疗超重或肥胖。RGL-2201：双靶点基因疗法今年 1 月 15 日，RGL-2201 在国内首次获批临床，用于新生血管性年龄相关性黄斑变性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212161008a44453ea&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212161008a44453ea&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","BK1191","LU0359201885.HKD","01276","LU0359201612.USD","LU1023057109.AUD","LU2543165471.USD"],"gpt_icon":0},{"id":"2590359451","title":"恒瑞医药（600276）披露召开2025年第二次临时股东会通知，12月11日股价上涨0.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590359451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590359451?lang=zh_cn&edition=full","pubTime":"2025-12-11 17:56","pubTimestamp":1765446968,"startTime":"0","endTime":"0","summary":"截至2025年12月11日收盘，恒瑞医药报收于63.4元，较前一交易日上涨0.03%，最新总市值为4207.98亿元。近日，恒瑞医药发布关于召开2025年第二次临时股东会的通知。公告显示，江苏恒瑞医药股份有限公司将于2025年12月31日召开2025年第二次临时股东会，会议采取现场与网络投票相结合方式，网络投票通过上海证券交易所系统进行。股权登记日为2025年12月22日，A股股东可参会。股东可于2025年12月23日办理登记。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100029366.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1997245094.SGD","LU1580142542.USD","LU1655091616.SGD","LU1023057109.AUD","LU2580892789.USD","BK0028","LU2495084118.USD","LU0405327494.USD","LU2289578879.USD","BK0196","BK0012","LU2580892862.HKD","BK0060","LU0405327148.USD","LU2097828714.EUR","LU2097828805.USD","LU1064130708.USD","LU1146622755.USD","BK0183","LU1255011170.USD","LU0359201885.HKD","LU1969619763.USD","BK1191","BK0188","600276","LU2097828631.EUR","LU2097828474.EUR","LU2328871848.SGD","LU2097828557.USD","LU0359202008.SGD","LU2148510915.USD","01276","LU1997244956.HKD","LU1997245177.USD","LU2543165471.USD","LU1820825898.SGD","LU1781817850.SGD","LU0359201612.USD","LU1328615791.USD","LU2488822045.USD","LU1064131003.USD","BK0239"],"gpt_icon":0},{"id":"2590757998","title":"每日卖空追踪 | 恒瑞医药 12月11日卖空量成交4.02万股，卖空比例为1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590757998","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590757998?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:30","pubTimestamp":1765441819,"startTime":"0","endTime":"0","summary":"恒瑞医药北京时间12月11日，跌0.6%，卖空量成交4.02万股，较上一交易日减少94.64%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163345979c67a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211163345979c67a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","LU0359201612.USD","LU0359202008.SGD","01276","LU1023057109.AUD","LU2543165471.USD","LU0359201885.HKD"],"gpt_icon":0},{"id":"2590598460","title":"瑞银：料今年香港新股融资规模将重夺全球首位 明年新股集资额逾3000亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590598460","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590598460?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:36","pubTimestamp":1765438607,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞银全球投资银行部副主席及亚洲企业客户部联席主管李镇国表示，今年港股IPO市场募集资金已达到2024年全年总额的2.1倍，并预计港交所将在2025年重新获得排行第一的IPO融资规模，料明年IPO集资额可逾3000亿港元。其中，宁德时代上市募资53亿美元，成为2023年以来全球最大IPO，并带动紫金黄金、三一重工、赛力斯、恒瑞医药、三花智控、海天味业、奇瑞汽车等多家龙头企业完成超10亿美元融资，占据全球十大IPO中的四席。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380331.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["81810","LU0831093199.SGD","BK1589","601318","HXXD.SI","LU0898667661.SGD","LU2293587155.HKD","03750","HBBD.SI","LU1048588211.SGD","LU0072462343.USD","01276","MIUmain","LU0348783233.USD","06031","PAImain","LU1880398471.USD","LU1196710864.SGD","03145","BK1193","BK1591","03288","LU0326950275.SGD","09927","81211","82318","LU0320764755.SGD","LU0477156797.USD","PNGAY","LU0868486357.SGD","09973","BK1588","01929","ALBmain","LU1868837565.USD","LU0890818403.SGD","HPAD.SI","HYDD.SI","002594","02601","LU1105468828.SGD","89988","BYDDY"],"gpt_icon":1},{"id":"2590305967","title":"交银国际：医保商保目录落地 多元支付体系创新药增量空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2590305967","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590305967?lang=zh_cn&edition=full","pubTime":"2025-12-10 14:26","pubTimestamp":1765348009,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，予内地医药行业领先评级。国家医保局召开“2025年创新药高质量发展大会”，正式公布本轮医保谈判和商保创新药目录协商结果。同时，商保资金的引入将为创新药支付带来重要增量资金，未来商业健康险有望与基本医保错位发展，为多元化支付体系的建立奠定基础。该行看好新纳入品种/适应症在2026年的销售增长潜力，尤其是康方生物等潜在大单品的增量释放空间。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0417516738.SGD","LU2097828714.EUR","01177","LU1969619763.USD","BK1147","LU0348766576.USD","LU2778985437.USD","BK1583","LU0359201612.USD","LU0417516902.SGD","03329","LU0348735423.USD","LU0359202008.SGD","IE00B5MMRT66.SGD","LU0540923850.HKD","LU2097828631.EUR","LU2097828557.USD","01276","LU0348825331.USD","LU1961090484.USD","BK1191","LU0634319403.HKD","IE00BZ08YS42.EUR","LU0502904849.HKD","01801","IE00BPRC5H50.USD","LU0348783233.USD","LU0561508036.HKD","06978","BK1515","HK0000165453.HKD","BK1574","LU0359201885.HKD","BK1521","LU2097828474.EUR","LU2476274308.USD","LU0417516571.SGD","LU0348767384.USD","LU2242644610.SGD","LU2488822045.USD","159992","LU2399975544.HKD","09926","LU2097828805.USD","BK1161","IE00B543WZ88.USD","LU2328871848.SGD","LU0348784397.USD","LU0348827113.USD","BK1589"],"gpt_icon":0},{"id":"2590340622","title":"恒瑞，龙头的底蕴","url":"https://stock-news.laohu8.com/highlight/detail?id=2590340622","media":"商图药讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590340622?lang=zh_cn&edition=full","pubTime":"2025-12-09 19:30","pubTimestamp":1765279829,"startTime":"0","endTime":"0","summary":"后续两年恒瑞医药的BD交易更进一步，与默沙东、GSK等公司达成了可圈可点的合作授权，BD已经成为恒瑞业务增长的重要驱动力之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209203837a72d718f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251209203837a72d718f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359202008.SGD","LU0359201612.USD","LU2543165471.USD","LU0359201885.HKD","BK1191","01276","LU1023057109.AUD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.hrs.com.cn","stockEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.0105},{"period":"3month","weight":-0.1453},{"period":"6month","weight":0.2594},{"period":"1year","weight":0.6425},{"period":"ytd","weight":0.6425}],"compareEarnings":[{"period":"1week","weight":-0.0053},{"period":"1month","weight":-0.0533},{"period":"3month","weight":-0.0306},{"period":"6month","weight":0.0809},{"period":"1year","weight":0.2833},{"period":"ytd","weight":0.2776}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA）修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼痛管理、神经系统疾病、眼科、肾病等领域。该公司主要在国内外市场开展其业务。","exchange":"SEHK","name":"恒瑞医药","nameEN":"HENGRUI PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"恒瑞医药,01276,恒瑞医药股票,恒瑞医药股票老虎,恒瑞医药股票老虎国际,恒瑞医药行情,恒瑞医药股票行情,恒瑞医药股价,恒瑞医药股市,恒瑞医药股票价格,恒瑞医药股票交易,恒瑞医药股票购买,恒瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"恒瑞医药(01276)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供恒瑞医药(01276)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}